Illumina (NASDAQ:ILMN) Stock: Insider Scott Ericksen Sells 267 Shares

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 267 shares of the business’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total transaction of $58,141.92. Following the completion of the sale, the chief accounting officer directly owned 14,029 shares of the company’s stock, valued at approximately $3,054,955.04. This trade represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Down 1.2%

Shares of NASDAQ:ILMN traded down $2.54 during trading on Friday, reaching $207.01. 1,229,158 shares of the company were exchanged, compared to its average volume of 2,291,458. The firm has a market capitalization of $31.30 billion, a PE ratio of 35.63, a P/E/G ratio of 2.84 and a beta of 1.46. The business’s fifty day simple moving average is $249.02 and its 200-day simple moving average is $179.64. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.34 earnings per share. On average, research analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Stephens downgraded Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a research report on Friday, October 23rd. Piper Sandler raised their price target on Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Finally, Argus upped their price objective on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $244.24.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently bought and sold shares of ILMN. BlackRock Inc. purchased a new stake in shares of Illumina during the 2nd quarter worth $3,374,423,000. Primecap Management Co. CA purchased a new position in Illumina in the second quarter valued at about $617,981,000. Jupiter Topco LLC purchased a new position in Illumina in the second quarter valued at about $358,652,000. WCM Investment Management LLC raised its holdings in Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Illumina in the second quarter worth about $293,846,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Key Illumina News

These are some of the ILMN news items that stood out recently:

• Positive Sentiment: An updated valuation estimate raised Illumina’s fair value to $261.45 per share from $248.90, offering a potential upside reference. Illumina Stock Sees Modest Fair Value Lift
• Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
• Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.